Company intelligence / Profile preview

CipherX

Ownership: Private
Development stage: Preclinical

Overview

CipherX has developed MicroDot Technology, a microneedle-based patch system that enables pain-free, hygienic, at-home permanent tattoos. The company's first commercial product allows users to design and order custom tattoos online and apply them themselves without needles or pain. The technology eliminates scarring risk and blood-borne disease transmission associated with traditional tattooing methods. Clinical results are not applicable as this is a consumer health/device innovation rather than a pharmaceutical therapy.

Therapeutic areas: Dermatology
Modalities: DevicePatch-based tattoo application device
Industry: Consumable Medical Devices

Partnerships

No major pharma/biotech partnerships disclosed as of June 2025.

Beyond the preview

Go deeper on CipherX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CipherX.

Explore the full profile